Biotech Sector Performance February 2014: Red Hot But...

Friday's sell off was a tumultuous end to what was a great month for the biotech sector. Here's where the sector stands two months into the year:


IBB Chart
IBB data by YCharts

Recall, the IBB was +8% at the end of January. 

About Friday's selloff. This is what it looks like mapped against the entire week's trading. We've seen dips like this before in the biotech bull market and they were all bought aggressively. Monday's trading will be interesting to watch.

IBB Chart
IBB data by YCharts


Here's how the big-cap biotechs are performing year to date:


CELG Chart
CELG data by YCharts

The best-performing biotech and drug stocks after two months of 2014:

1. Intercept Pharma (ICPT) + 501%
2. Tekmira Pharma (TKMR) +166%
3. Rexahn Pharma  (RNN)+165%
4. Imprimis Pharma (IMMY) +157%
5. Retrophin Pharma  (RTRX) +152%


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Google's YouTube in Hot Water Again Over Ads on Inappropriate Content

Google's YouTube in Hot Water Again Over Ads on Inappropriate Content

Should Tesla Nominate a New CEO Not Named Elon Musk?

Should Tesla Nominate a New CEO Not Named Elon Musk?

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Aerospace Propels GE, Honeywell, Bodes Well for Boeing, Lockheed

Aerospace Propels GE, Honeywell, Bodes Well for Boeing, Lockheed

Video: How to Select Mutual Funds in Your 401(k)

Video: How to Select Mutual Funds in Your 401(k)